Compare CLLS & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLLS | PFO |
|---|---|---|
| Founded | 1999 | 1991 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.8M | 110.8M |
| IPO Year | 2014 | N/A |
| Metric | CLLS | PFO |
|---|---|---|
| Price | $0.97 | $8.30 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.45 | N/A |
| AVG Volume (30 Days) | ★ 55.6K | 24.3K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $8.32 |
| 52 Week High | $5.45 | $9.73 |
| Indicator | CLLS | PFO |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 36.25 |
| Support Level | N/A | N/A |
| Resistance Level | $1.28 | $9.24 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 20.37 |
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.